HOLD existing position; add on pullback to 492-501 zone with 21.8-22.2x forward entry multiple, hard stop at 492, 1-1.5% incremental sizing

• BRK-B at 22.7x forward P/E with PEG of 10.06 represents full price for a compounder; trailing multiple of 12.7x is selection bias as markets price on forward expectations
• Stock at upper end of 52-week range, up approximately 79% over five years; MACD has rolled over with three lower highs since November; volume-weighted moving average declining
• Target add zone: 492-501 (50-week dollar pullback), target entry multiple approximately 21.8-22.2x forward P/E, hard stop at 492
• Greg Abel unproven as new CEO executing first major acquisition; $6.8B Taylor Morrison deal closed but $359B in T-bills and $323B equity portfolio present key-person and regime-change risk
• Abel positioning $18B in net investment sales in Q2 likely signals Buffett-era discipline to reduce equity exposure at elevated valuations, not positioning for deployment
• Hawkish macro with Polymarket pricing 89% odds of zero cuts creates broad multiple compression headwind across equity holdings including BNSF, utilities, and equity portfolio mark-to-market
• Buffett's unusual naming of J&J and Merck instead of BRK as defensive positioning is a yellow flag signaling elevated equity valuations rather than humility theater
• Long BRK-B, short rate-sensitive tech pair trade introduces leveraged two-legged expression with added basis risk, margin risk, crowding risk, and drawdown risk inappropriate for conservative mandates
• Existing position justified by defensive ballast, fortress balance sheet, accelerating buybacks, beta of 0.61, and TTM free cash flow base of approximately $72 billion
• Conservative mandate prioritizes capital preservation across cycles over maximizing expected return; leaving return on table by not adding is defensible while adding at top of range is not

→ vs aggressive: BRK-B at 22.7x forward P/E with PEG of 10.06 is not 'reasonable'; calling it cheap because trailing multiple is 12.7x is selection bias as markets price on forward expectations not GAAP noise

→ vs aggressive: 'Build into strength, not weakness' is market-timed discipline that produced every major drawdown of last two decades; MACD rolled over, three lower highs since November, adding here into 492-501 zone with hard stop at 492 is process not timidity

→ vs aggressive: Treating Greg Abel's first major acquisition as a catalyst to add risk is backwards; first-year CEOs with hundreds of billions to allocate make mistakes; $359B in T-bills and $323B equity portfolio present key-person and regime-change risk that should be underwritten conservatively until proved otherwise

→ vs aggressive: $18B in net investment sales in Q2 reading as 'positioning for big deployment' ignores historically correct Buffett-era discipline that treats elevated valuations as signal to reduce exposure; conservative posture is to assume cautious read until Abel proves otherwise

→ vs aggressive: Hawkish-macro-is-your-friend argument treats regime-level multiple compression headwind as name-specific tailwind; higher discount rates hit every long-duration cash flow including BNSF, utilities, and equity portfolio mark-to-market regardless of float economics

→ vs aggressive: Dismissal of Buffett pointing investors to J&J and Merck as 'humility theater' ignores that Buffett has spent six decades steering investors to his own stock when cheap and away when not; unusual defensive healthcare name-calling is information and a yellow flag

→ vs aggressive: Long BRK-B, short rate-sensitive tech pair trade introduces leveraged two-legged expression with basis risk, margin risk, crowding risk, and drawdown risk that does the opposite of risk management; amplifies both directions instead of capping downside

HOLD existing 2-3% portfolio position; structure add-on as scaled entries across $492-501 zone with $492 hard stop; reject pair trade; do not add above $501

• HOLD on existing position is correct based on fortress balance sheet, $72B TTM free cash flow, beta of 0.61, buyback floor, and diversified operating businesses
• Current market is range-bound between $501 and $509 with 50 SMA at $501, 20 SMA at $508.86, and VWMA at $504.77 creating resistance
• MACD has rolled over with negative histogram, suggesting not to chase at current levels
• Long-term structure intact with 200 SMA at $492 and higher-low pattern since April
• Scaled entry recommended: half of 1-1.5% incremental allocation in $498-501 zone if reached, reserve other half for $492-496 if 200 SMA tested
• Position sizing as primary risk control limits maximum loss on add-on to roughly 50-75 basis points of total portfolio
• Reject aggressive analyst's case on three fronts: trailing vs forward P/E gap does matter in selloffs, $18B in sales historically signals elevated valuations not deployment, and pair trade introduces basis/margin/crowding risk
• Reject conservative analyst's over-reliance on 200 SMA magnet theory as overconfidence in technical patterns
• Buffett's healthcare name-checks (J&J, Merck) are consistent with his lifelong behavior of deflecting attention from BRK, not necessarily a valuation confession
• Pair trade rejected as it changes risk profile and should not be levered through the HOLD; express relative-value view through separate underweight tech sizing instead
• Macro: BRK performs as defensive compounder in slow-growth tight-policy regime; hawkish headwind real but float and T-bill yields improve in hard-rate environment

→ vs aggressive: The trailing P/E versus forward P/E gap is not irrelevant noise—if market de-rates from 22.7x to 18x, that is a 20% drawdown regardless of operating business quality; good business doesn't make current entry price compelling, it makes existing position defensible

→ vs aggressive: The $18B in investment sales historically signals elevated valuations trigger selling, not buying; betting that an unproven new CEO will be more aggressive at cycle peaks than Buffett is speculative without higher conviction

→ vs aggressive: Pair trade introduces basis risk, margin risk, and crowding risk—holding BRK-B captures upside anyway, and short leg doesn't save either side in a liquidity event; this is a different mandate

→ vs conservative: The 200 SMA at $492 is not a fundamental price target—there's no earnings catalyst or specific event pointing there; treating it as probable entry is overconfidence in technical patterns; sometimes it catches, sometimes stock grinds higher without the pullback

→ vs conservative: Buffett's healthcare name-checks are consistent with his lifelong behavior of saying 'opportunity is elsewhere right now'; treating a yellow flag as a red one overweights this signal; he deflected to S&P 500, Coca-Cola, Amex, Apple, BofA at various cycles